Search Results - "Espinosa Olarte, P."

The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications by Soldevilla, B., Carretero-Puche, C., Gomez-Lopez, G., Al-Shahrour, F., Riesco, M.C., Gil-Calderon, B., Alvarez-Vallina, L., Espinosa-Olarte, P., Gomez-Esteves, G., Rubio-Cuesta, B., Sarmentero, J., La Salvia, A., Garcia-Carbonero, R.

“…Solid tumour growth is the consequence of a complex interplay between cancer cells and their microenvironment. Recently, a new global transcriptomic immune…”
Get full text

P-350 Maintenance trastuzumab in the setting of second-line treatment in HER2 overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma: Experience of our centre by López, F. López, Barrio, R. Yarza, Olarte, P. Espinosa, Gomez-Martin, C.

Get full text

424P Could total neoadjuvant therapy (TNT) become a new standard in locally advanced rectal cancer (LARC)? A systematic review and meta-analysis (MA) of TNT vs. standard chemoradiotherapy (CRT) by Martínez, M.C. Riesco, Grávalos, C., Espinosa-Olarte, P., La Salvia, A., Modrego-Sánchez, A., Robles, L., Garcia-Carbonero, R.

Get full text

1686TiP Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations by Macarulla, T., Castet, F., Lobo de Mena, M., Garcia-Carbonero, R., Martinez de Castro, E., Munoz Martin, A.J., Pazo Cid, R.A., Grana Suarez, B., Gallego Plazas, J., Alvarez, R., Ales Diaz, I.C., Gallego Jimenez, I., Laquente, B., Rodriguez, M., García Paredes, B., Cano Osuna, M.T., Ruiz de Mena, I., Fabregat-Franco, C., Espinosa Olarte, P., Aranda Aguilar, E.

Get full text

1158MO Metabolomic profile of advanced neuroendocrine cancer patients by Soldevilla, B., Lens-Pardo, A., Lopez-Lopez, A., Carretero-Puche, C., La Salvia, A., Riesco-Martinez, M.C., Espinosa-Olarte, P., López-Gonzálvez, Á., Barbas, C., Garcia-Carbonero, R.

Get full text

1174P RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study by Grande, E., Espinosa-Olarte, P., Serrano, R., Jimenez, P., Alonso, T., Benavent, M., Castillón, J. Capdevila, Lacasta, A., Tur, R. Yaya, Carmona, A., Gallegos, I., Rodríguez, R.M., Trujillo, A.O. Castillo, Cerrillo, J. Molina, Hernando, J., Martinez, A. Bujedo, Garcia-Carbonero, R.

Get full text

1164P Prognostic value of miRNA profiling in neuroendocrine neoplasias (NENs) from lung and gastroenteropancreatic (GEP) origin by Espinosa-Olarte, P., Soldevilla, B., Carretero-Puche, C., Molina-Pinelo, S., Robles, C., Benavent, M., Gomez-Izquierdo, L., Morales-Burgo, P., Jimenez-Fonseca, P., Fierro-Fernandez, M., La Salvia, A., Lens-Pardo, A., Riesco-Martinez, M.C., Garcia-Carbonero, R.

Get full text